ASH 2022 Conference Coverage
ASH 2022 Phase 1b/2a Study Results From Dose-Escalation: AZD4573 (CDK9i) & Acalabrutinib in R/R DLBCL
By
ASH 2022 Conference Coverage
FEATURING
Paolo Strati
By
ASH 2022 Conference Coverage
FEATURING
Paolo Strati
Login to view comments.
Click here to Login